Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosisSeong Il Seo, Lajos Gera, Haiyen E Zhau, et al.
Cancer Research|September 20, 2006
beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasisWen-Chin Huang, Daqing Wu, Zhihui Xie, et al.
Oncogene|September 13, 2003
Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cellsMeagan A McJilton, C Van Sikes, Ginger G Wescott, et al.
The Journal of Biological Chemistry|November 29, 2012
Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transitionShumin Zhang, Xu Wang, Shareen Iqbal, et al.
Translational Oncology|June 4, 2023
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical modelsLijuan Bai, Xin Li, Yang Yang, et al.
British Journal of Cancer|July 20, 2023
Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical modelsXin Li, Yanhua Chen, Lijuan Bai, et al.
Theranostics|June 7, 2021
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancerXin Li, Lajos Gera, Shumin Zhang, et al.
Clinical Genitourinary Cancer|October 10, 2006
Stromal-epithelial interaction in prostate cancer progressionLeland W K Chung, Wen-Chin Huang, Shian-Ying Sung, et al.
Nature Communications|March 18, 2021
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancerBaotong Zhang, Yixiang Li, Qiao Wu, et al.
British Journal of Cancer|April 19, 2025
Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancerXin Li, Kenza Mamouni, Rui Zhao, et al.
Pageof 6